Intuitive Surgical, Inc. (NASDAQ:ISRG) Shares Bought by Scientech Research LLC

Scientech Research LLC grew its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 202.0% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 4,542 shares of the medical equipment provider’s stock after acquiring an additional 3,038 shares during the period. Scientech Research LLC’s holdings in Intuitive Surgical were worth $2,021,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. One Wealth Management Investment & Advisory Services LLC lifted its position in shares of Intuitive Surgical by 3.4% during the 2nd quarter. One Wealth Management Investment & Advisory Services LLC now owns 697 shares of the medical equipment provider’s stock valued at $310,000 after acquiring an additional 23 shares during the period. Indiana Trust & Investment Management CO lifted its position in shares of Intuitive Surgical by 5.3% during the 2nd quarter. Indiana Trust & Investment Management CO now owns 500 shares of the medical equipment provider’s stock valued at $222,000 after acquiring an additional 25 shares during the period. Hoxton Planning & Management LLC raised its position in shares of Intuitive Surgical by 4.9% during the 2nd quarter. Hoxton Planning & Management LLC now owns 534 shares of the medical equipment provider’s stock worth $238,000 after purchasing an additional 25 shares during the last quarter. First Affirmative Financial Network raised its position in shares of Intuitive Surgical by 2.7% during the 2nd quarter. First Affirmative Financial Network now owns 996 shares of the medical equipment provider’s stock worth $443,000 after purchasing an additional 26 shares during the last quarter. Finally, Moors & Cabot Inc. raised its position in shares of Intuitive Surgical by 2.3% during the 2nd quarter. Moors & Cabot Inc. now owns 1,159 shares of the medical equipment provider’s stock worth $516,000 after purchasing an additional 26 shares during the last quarter. 83.64% of the stock is currently owned by institutional investors and hedge funds.

Intuitive Surgical Stock Up 0.4 %

Shares of NASDAQ ISRG opened at $486.33 on Friday. Intuitive Surgical, Inc. has a 52-week low of $254.85 and a 52-week high of $496.18. The firm has a fifty day moving average of $472.54 and a 200-day moving average of $427.52. The stock has a market capitalization of $172.82 billion, a PE ratio of 87.79, a P/E/G ratio of 5.39 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG) last announced its quarterly earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share for the quarter, topping analysts’ consensus estimates of $1.54 by $0.24. Intuitive Surgical had a net margin of 27.65% and a return on equity of 13.04%. The firm had revenue of $2.01 billion during the quarter, compared to analysts’ expectations of $1.97 billion. During the same period in the prior year, the company earned $1.18 EPS. The firm’s revenue was up 14.5% on a year-over-year basis. Equities research analysts expect that Intuitive Surgical, Inc. will post 5.22 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on ISRG. Barclays lifted their price objective on Intuitive Surgical from $430.00 to $490.00 and gave the stock an “overweight” rating in a research report on Thursday, July 18th. Stifel Nicolaus lifted their price objective on Intuitive Surgical from $430.00 to $475.00 and gave the stock a “buy” rating in a research report on Friday, July 19th. Truist Financial lifted their price objective on Intuitive Surgical from $450.00 to $515.00 and gave the stock a “buy” rating in a research report on Tuesday, July 16th. Evercore ISI cut their price objective on Intuitive Surgical from $425.00 to $410.00 and set an “in-line” rating for the company in a research report on Friday, July 19th. Finally, Robert W. Baird lifted their price objective on Intuitive Surgical from $487.00 to $503.00 and gave the stock an “outperform” rating in a research report on Friday, July 19th. Six analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $446.45.

Insider Buying and Selling

In related news, Director Amal M. Johnson sold 2,943 shares of the company’s stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $443.30, for a total transaction of $1,304,631.90. Following the completion of the sale, the director now directly owns 12,275 shares of the company’s stock, valued at approximately $5,441,507.50. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Intuitive Surgical news, SVP Henry L. Charlton sold 40,243 shares of the company’s stock in a transaction dated Friday, August 23rd. The shares were sold at an average price of $486.84, for a total value of $19,591,902.12. Following the completion of the transaction, the senior vice president now directly owns 3,001 shares of the company’s stock, valued at approximately $1,461,006.84. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Amal M. Johnson sold 2,943 shares of the company’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $443.30, for a total transaction of $1,304,631.90. Following the completion of the transaction, the director now directly owns 12,275 shares of the company’s stock, valued at $5,441,507.50. The disclosure for this sale can be found here. In the last three months, insiders sold 53,120 shares of company stock valued at $25,528,753. Company insiders own 0.90% of the company’s stock.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.